Professor Robert J Thomas

	Professor Robert J Thomas Mb ChB MRCP MD FRCR
	Teaching posts \| Specialist interests \| Editorial experience \| Research interests \| Prizes \| Publications \| Books \| Contact



Receive our monthly lifestyle research newsletter Email:

Foreword by Paula Radcliffe -download free

Professor Robert Thomas is a practicing consultant, cancer specialist, with 26 year’s experience in patient care. After formal training at the Royal Marsden, National Hospital for Neurology, Royal Free and Middlesex Hospitals London, he now leads chemotherapy services at the Primrose Oncology & Research Unit, Bedford and treats patients with radiotherapy and brachytherapy at Addenbrooke’s Hospital, were he is also a designated clinical teacher at Cambridge University.

At Addenbrooke's he was clinical lead for the introduction of prostate brachytherapy where now over 240 men have been successfully treated. He manages patients with radiotherapy using conventional, conformal, intensity modulated (IMRT), image guided (IGRT) and tomotherapy techniques. His systemic medical practice is based at Bedford at the designated cancer (The Primrose Unit) and at The Manor Hospital Biddenham. Specialist interests include the care of patients with breast, prostate, bladder, kidney and bowel cancer using chemotherapy, hormone therapy and biological agents.

Teaching posts
As a clinical tutor at Cambridge University he teachers medical students in clinic and at the bedside. He scored the highest grade "outstanding clinical teacher" from every student for three years running. At Cranfield University he lectures post graduate translational medicine students and is co-supervisor of MSc and PHD students. He designed and teaches on the UK's first cancer training course in cancer rehabilitation for exercise professionals (level 4) and gives regular lectures on the evidence for self help lifestyle strategies after cancer to survivorship groups and international medical conferences.

Editorial experience
Editorial input into the 2000 national NHS Cancer plan, the DoH review of complementary medicine; The NICE committee on palliative and supportive medicine. Editor of the Macmillan Cancer Relief survivorship evidence review document and wrote a number of their lifesyle patient information booklets. Deputy editor of the British Journal of Cancer Management and editor of the the medical journal "Focus on cancer medicine". He is editor of the cancer treatment and lifestyle advice website cancernet.co.uk and prostate-cancer.co.uk.

Research interests
He leads a busy research team which recruits enthusiastically in range of National (NCRN) studies involving chemotherapy, biological therapies, hormones and radiotherapy. He was Europe's highest recruiter in three large pharmaceutical trials and was the UK's highest recruiter in the diet Comply study and prostate relapse outcome trial. Despite a long history of basic scientific and laboratory research his own academic interests now focus on ways to improve patient’s quality of life, reduce their side effects and improve their understanding of their disease and treatment options. He has designed, conducted and published six nationally ethically approved scientific studies as well as a number of cost effectiveness studies linked to Cranfield School of Management, Cranfield, Oxford, Cambridge and Hull Universities. The methodology for this research is also now being taught to colleagues and students internationally in formal teaching programs, medical conferences and invited lectures.

He has a particularly strong research interest on how lifestyle interacts with the cancer process and how an optimal lifestyle can improve quality of life and disease outcome following a diagnosis of cancer. As well as a number of practical lifestyle strategies for patients, his team have designed and conducted the worlds largest prospective lifestyle study in men with prostate cancer. He has designed and is conducting the world's first double blind RCT of and broad spectrum nutritional supplement for prostate cancer (Pomi-T).

What size chest tube for pleural effusions? Dr Robert J Thomas, Dr S M Sagar. British Journal of Hospital Medicine (l990). Vol 43. p.53.

An analysis of surveillance for stage one combined teratoma/seminoma of the testis. Thomas R, Dearnaley D, Horwich A. British Journal of Cancer. 1996, 74: 59-63.

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. R J Thomas, N James, D Guerro, S Asley , A Gregor, M Brada. Radiotherapy & Oncology (1995). Vol,.33, pp.113-116.

Speech and language disorders in patients with high grade gliomas and its influence on survival. R. J. Thomas, M O'Conner, S Ashley, M Brada. Journal of Neuro-Oncology (1995). Vol.23: p.265-270.

Pneumothorax and palliative pleural aspiration - an audit of technique. Dr Robert J Thomas, Dr J Maher. Palliative Medicine (1993): 7: pp 67-71.

Metastatic Parathyroid Carcinoma. Dr Robert J Thomas, Dr A Cassoni. Journal of the Royal Society of Medicine (1992). 85(3) 92;182.

Modifying the Barthel performance index score for use with patients with brain tumours. R.J.Thomas D Guerrero, F Hines, M Brada. European Journal of Cancer Care (1995) Vol.4, pp. 63-68.

Modifying the Barthel index for use in patients with brain tumours - an update. R Thomas. European journal of cancer care February 1997, 6:2

Distribution kinetics of radiolabelled monoclonal antibodies in experimental tumours following interstitial and systemic administration. Dr R J Thomas, P Carnochan, M Brada - Radioactive isotopes in Nuclear Medicine and research. 1994

Patients preferences for video cassette recorded information. Effect of age, sex and ethnic group.Thomas R, Deary A, Kaminski E, Diane Stockton (statistician), N De Zeeuw. The European Journal of Cancer Care. Vol 2. 8 Jan, 1999

Adjuvant breast cancer drugs - blockbusters or bankrupters. Thomas R, O’sullivan B, et al. (2006).British Journal of Cancer Management 2(3): 5-9.

Forewarned is forearmed – benefits of preparatory information on video casette for patients receiving chemotherapy and radiotherapy- a randomised trial. Thomas R, Daly M, Perryman B, Stockton D EJC issue 36 (2000) 1536-1543.

Lessons Learnt from Raltitrexed – Quality Assurance, Patient Education and Intensive Supportive Drugs to Optimize Tolerability. R.J. Thomas, M. Williams, J. Garcia-Vargas Clinical Oncology (2003) 00:1-6.

Examining quality of life issues in relation to endocrine therapy for breast cancer.Robert Thomas. American Journal of Clinical Oncology 2003. Vol. 26, No. 4, pp S40-S44

Measuring information strategies in oncology – developing an information satisfaction questionnaire. Thomas R, Kaminski E, Stanton E and Williams M. European Journal of Cancer Care, 2004, 13, 65-70.

To what extent does neutropenia impact on the ability to deliver planned chemotherapy in lymphoma? – The results of a UK neutropenia audit J Sweetenham;B Hancockb; R Pettengellc; A Pagliucad; R Thomase; P Hoskinf; A McMillang; M Joynerh; D Spooneri.

Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. R. Thomas, S. Godward, A. Makris, D. Bloomfield, A.M. Moody, M. Williams. Clinical Oncology (2004) 16: 485-491.

Dietary advice combined with a salicylate mineral and vitamin supplement (CV247) has some tumour static properties - a phase II study. R Thomas, M Blades, M Williams and S Godward . Nutrition & Food Science 2005, Volume 35 Issue 6, 436- 451

Can switching to Aromatase inhibitors in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? (2008) R Thomas, C Marshall, M Williams, L Walker. British Journal Of Cancer (98) 1494-1496

The financial implications of switching to adjuvant exemestane in patients with early breast cancer British Journal of Cancer (2008) Thomas, M Williams, C Marshall, J Glen & M Callam (2009) Clinical Focus Cancer Medicine, 1(3):82–87.

Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer" Breast Cancer Research and Treatment. Thomas R, Glen J, Marshal C (2009) Volume 117 Issue 2 page 289.

A randomised double-blind phase II study of lifestyle counselling and salicylate compounds in patients with progressive prostate cancer. (2009) R Thomas, R Oakes, J Gordon, S Russell, M Blades and M Williams. Nutrition & Food Science (39) 3, 295-305.

The total hospital and community costs of managing patients with relapsed breast cancer. 2009 R Thomas, M Williams, J Glen, M Callam. British Journal of Cancer 100, pp 598-600.

A prospective survey of chapped lips and cold sores during chemotherapy. Focus on cancer Medicine 2010 R Thomas, T Taylor & M. Williams 2(1): 8-14.

Endometrial carcinoma - Adjuvant locoregional RJ Thomas,Clinical Oncology. 1996 8: 140-146.;Patient Information materials in Oncology: Are they needed and do they work? Thomas R, and H Thorton. How to deal with the complexities of patient consent? Robert Thomas. Pulse Clinical pp42-4, 2003.

The changing face of informed consent. R Thomas. British Journal of Cancer Management. Summer 2004 Vol. 1 No. 1. pp 11-15.

What are the costs of not using rhEPO to treat anaemia in cancer. Robert Thomas. Focus on anaemia in cancer. 2002, Vol 3, issue 2, pp52-53.

NICE guidance on supportive and palliative care – Implications for Oncology Teams. Dr R Thomas and Professor Alison Richardson. Clinical Oncology (2004) 16: 420-424.

The NICE guidance on supportive and palliative care. Dr Robert Thomas and Professor Alison Richardson. British Journal of Cancer Management 2004; Vol. 1 No. 3.

Restructuring supportive care – Affect on oncology practice. R Thomas. British Journal of Cancer Management. Vol.2 No.4 April 2005.p12-15

Anaemia fatigue and Epoeitin in Oncology R Thomas. British Journal of Cancer Management. Vol.2 April No. 4, 2005.

Complemenatry and alternative medicine evidence online for cancer. J Richardson, K Pilkington and R Thomas. BJCM 2005, vol.2, no.2, pp10-12.

Diet, salicylates and their effect on prostate cancer. 2006. Robert Thomas, Cathryn woodward and Peter Williams. Brtitish Journal of Cancer Management voume 3, no. 1, pp 5-9.

Adjuvant breast cancer drugs- blockbusters or bankrupters. 2006 , Thomas R, Glen J, Callam M, british Journal of Cancer Management no.3, vol 24, pp 5-9

Can dietary intervention alter prostate cancer progresssion. 2007. Robert Thomas, Mabel Blades, madeleien williams. Nutrition & Food Science, 2007 vol 37, no.1 pp 24-36.

Cancer – the roles of exercise in prevention and progression Nutrition and Food Science 2007 Volume 37 Issue 5. Robert Thomas and Nichola Davies

Lifestyle During and after cancer Treatments Thomas R, Davies N. Clinical Oncology 2007, 19, pp 616-627.

Should oncology units establish Lifestyle Clinics?. Thomas R, Williams M, Davis N. Clinical Focus on Cancer Medicine 2008 (1) 2 38-48

Writing medical Papers . Dr Robert J Thomas. Journal of The Royal Society of Medicine August 1993

Evidenced based patient information - Local policies would be better than a national strategy. 1999, British Medical Journal, vol 318. page 462.

Further differential diagnosis of hilar masses. Dr Robert J Thomas. The British Journal of Radiology (1992). Vol.65, No.774, p.553.

Mistaken Hilar Mass. Dr Robert J Thomas, Dr G Duchesne. The British Journal of Radiology (1991). Vol.64, No.766, p.977-978.

The Tin-Tack sign in post irradiation scalp skin scales. Dr Robert J Thomas, Dr Neil Smith, Dr Margaret Spittle. British Journal of Dermatology (1992). Vol 126/1: 90

PET saves man. Robert Thomas, Madeleine Williams & Sally Old. British Journal of Cancer Management. Summer 2004 Vol. 1 No. 1, p22-23

Bevacizumab saves the day. R Thomas, Sanjay Raj, Ahmed Eldin. 2005. BJCM. Vol.2, number 2. p20-21.

Cetuximab – a new team player. Yassa Haba, Myrddin Rees, David Skipper, Robert Thomas. 2006 BJCN, vol 2, no.3 pp19-21.

A cool solution for docotaxel induced onycholysis: A case report of cold water baths to prevent docetaxel induced onycolysis PM Ding RJ Thomas Clinical focus on Cancer Medicine 2010 2(1): 18-19.

Olfactory sensations produced by high-energy photon irradiation of the olfactory receptor mucosa in humans. Stephen Sagar, Robert J Thomas, L. Loverock, Margaret Spittle.International Journal Radiation Oncology Biology Physics (1990). Vol 20, pp 771-776.

Dosimetry of intralesional 131I monoclonal antibody therapy in patients with recurrent high grade glioma. S. Chittenden, R. Thomas, G. Flux, T. Smith, M. Brada, M. Flower, R. Ott. 1995. (1). pp. 270-274.

Mathematical modelling of 3D intracranial radioisotope dose distribution. G Flux, R Thomas, R Ott, Eur. J. Nuclear Medicine. published July 1997

The verbally administered barthel index in patients with glioma. Dr L Brazil , Dr R Thomas, Dr M Brada. Radiation and Oncology, July 1995.

The Role and Activity of an Italian Volunteer Organisation providing Information and Emotional Support for Patients with Cancer. F. De lorenzo, c. Paglia i. Duce and U. Tirelli, R. Thomas,. G. Vecchio. Dipartimento di Biologia e Patologia Cellulare e Molecolare L. Califano, Universita Federico Napoli. Nov '98. Health communications June 1999.

An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole. C. Rose, O. Vtoraya, A. Pluzanska, N. Davidson, M. Gershanovich, R. Thomas, S. Johnson, et al. European Journal of Cancer 39 (2003) 2318-2327

To what extent does neutropenia impact on the ability to deliver plannedchemotherapy in lymphoma? – The results of a UK neutropenia audit J Sweetenhama*;B Hancockb; R Pettengellc; A Pagliucad; R Thomase; P Hoskinf; A McMillang; M Joynerh; DSpooneri. British Journal of Cancer 2004.

Complementary and Alternative Medicine Evidence On-Line (CAMEOL) For CancerJ Richardson, K Pilkington & Robert Thomas. Bristish Journal of Cancer Management accepted for december 2005, Volume 5.

Aloe Vera for preventing radiation-induced skin reaction: A systemic literature review. J Richardson, J Smith, M McIntyre, R Thomas, K Pilkington. Clinical Oncology. 2005, 17:478-484.

Information Satisfaction in Breast and Prostate Cancer Patients: Quality of Life Implications Nichola Davis & Robert Thomas

Empowering patients to make informed decisions by measuring their needs and satisfaction 2007 N Davies, R Thomas Clinical Focus Cancer Medicine vol 1 (issue1) pages 3-8

Black Cohosh for menopausal symptoms in women with breast cancer: A systematic literature review. Joanna Smith, Janet Richardson, Michael McIntyre, Rob Thomas, Karen Pilkington. http://rccm-host.wmin.ac.uk/cameo/

Davies , N.J. , Kinman, G., Thomas, R.J., and Bailey, T.A. (2008) Information satisfaction in breast and prostate cancer patients: Implications for quality of life. Psycho-Oncology, published online at http://www3.interscience.wiley.com/cgi-bin/abstract/117871474/ABSTRACT

Multimodal Image registration for radioimmunotherapy R. Thomas, G. Flux, M. Brada, R Ott. In Radioactive isotopes in Nuclear Medicine and research. 1995. p175-182

Intralesional radiolabelled MAb in experimental tumour. R Thomas, P Carnochan, S Eccles, M Brada. For; Radioactive isotopes in Nuclear Medicine and research. Jan 1999.

Empowering patients in Oncology by R Thomas, in “The Psychology of decision making” by Nova Publications 2008.

The internet and Oncology by R Thomas in “The oxford Handbook of Oncology” 2010.

Lifestyle after Cancer by R Thomas in “The oxford Handbook of Oncology” 2010

Olfactory sensations in Radiotherapy. Robert J Thomas, S Sagar , M Spittle. BIR Annual conference. Harrogate 1990. Abstract, British Journal of Radiology, Sept 1990.

Distal Muscle Involvement in a new category of Muscular Dystrophy. R Thomas, R Goodwin-Austen. The Midlands Annual Neurological Conference. Wolverhampton , June'86. Conference proceedings.

Diffusion characteristics of intralesionally administered 131I monoclonal antibody in patients with recurrent high grade glioma. R J Thomas, M Brada, P Carnochan G. Flux, N Kitchen, D Bigner, M Zalutsky. 10th International conference on Brain Tumour research. Voss , Norway . J of Neuro-Oncology. 1993. vol.15 suppl. pp.28.

Localisation of uptake in radioimmunotherapy using a stereotactic head frame. R J Thomas, G Flux, M Brada. Royal College of Radiologist annual conference 1993, Warwich. Clinical Oncology October 1993.

Image registration with the aid of a stereotactic head frame for radioimmunotherapeutic studies. British journal of Neurosurgery. (British Neuro-oncology group conference June 1993 ) RJ Thomas, G Flux, S Chittenden , B Cronin, R Ott, M Brada. British Journal of Neurosurgery. Dec 1993.

Multimodal Image registration for radioimmunotherapy - Surface landmark and frame based correlation in patients with recurrent high grade glioma. R. Thomas S, Chittenden,G. Flux, T. Smith, M. Brada, R. Ott. European J of Nuc Med. Jan 1994. Vol.21, pp7.

Speech and language disorders in patients with high grade gliomas and its influence on survival. R Thomas, M O'Conner, S Asley , M Brada. (First congress of the European Association for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.22.

Speech and language disorders in patients with high grade gliomas and its influence on survival. (British Neuro-oncology group conference June 1994 ). R Thomas, M O'Conner, S Asley , M Brada. British Journal of Neurosurgery. Dec1994.

Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas, M Brada. (Brit. Neuro-oncology group conference ). B J Neurosurg. Dec'94.

Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden , G. Flux, R. Ott, M. Brada. (British Neuro-oncology group conference July1994) British Journal of Neurosurgery. Dec 1995.

Intralesional 131I-labelled Mab therapy in patients with recurrent high grade glioma. R. Thomas , S Chittenden , G. Flux, R. Ott, M. Brada. (First congress of the European Association for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.68.

Acute morbidity following catheter implantation for interstitial brachytherapy and immunotherapy for glioma. P Doshi, R Thomas, R Beaney, D Thomas. (British Neuro-oncology group conference 1994) British Journal of Neurosurgery. Dec 1994.

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. R Thomas, N James, A Gregor, M Brada.. (1st congress of the European Ass. for Neuro-Oncology). 1994. Journal of Neuro-Oncology Vol.21, No.1. p.45.

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma. N James, R Thomas, D Guerro, S Asley , A Gregor, M Brada. ( BOA 1994). British Journal of Cancer July 1994, Vol. 70. Supplement XX11.

Intralesional 131-I labelled Mab therapy in patients with recurrent high grade gliomas. (BOA 1994). Thomas R, Flux G, Chittenden S, Hall A, Kitchen N, Thomas DGT, Bigner D, Zalutsky, Brada M. British Journal of Cancer July 1994, Vol. 70. Supplement XX11.

38)Verbally administered Barthel Index as functional assessment in brain tumour patients. R Thomas, L Brazil, M Brada (The first congress of the European association for Neuro-oncology April 1994). 21, (1), p.71.

Monoclonal antibodies in Neuro-Oncology - a review. R Thomas. Royal College of Radiologist annual conference 1994, Warwich. Abstract. Clinical Oncology October 1994.

Multimodal image registration for radioimmunotherapy. Surface Landmark and frame based correlation in patients undergoing intralesional 131-I MAb therapy for recurrent high grade glioma. (BOA 1994) Thomas R, Flux G, Chittenden C, Ott B, Brada M. British Journal of Cancer July 1994, Vol. 70. Supplement XX11.

The use of multimodality imaging to monitor intralesional therapy. G. Flux, R. Thomas, S.Chittenden, T. Smith, M. Brada, M. Flower, R. Ott. ( W.F.N.M.B Sydney 1994) European Journal of Nuclear Medicine. September 1994.

Stage one mixed teratoma/seminoma - outcome and patterns of failure following surveillance. Thomas R , Dearnaley D and Horwich A. (BOA 1995). British Journal of Cancer. July 1995.

Distribution kinetics of radiolabelled MAbs in experimental tumours following interstitial and systemic administration. Dr R J Thomas, P Carnochan, M Brada. (ECCO 1995) Radiotherapy and Oncology. Nov. 1995.

Lymphography - its role in the radiotherapy planning of carcinoma of the cervix. Thomas R, Wilkins M, Blake P. ( Conference: Brachytherapy and external beam radiotherapy for carcinoma of the cervix). February 1996. British Journal of Radiology.

Carcinoma of the cervix. the role of lymphography in individualising the planning target volume. (BOA 1996). R Thomas, M Wilkins, N Hinds, P Blake. For British Journal of Radiology; 69:579

Patients attitudes towards video directed information - A multicentre study. Deary A, Kaminski E, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1389.

Do patient's want the same information as the GP? Kaminski E, Deary A, Thomas R. The European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1391.

Patient preferences for and satisfaction to a breast care nurses specialist. Shingler G, Smith S, Thomas R. European Journal of Cancer. (ECCO) 1997. Vol. 33, Supplement 8, 1397.

Cancer patient education and information: Development of a new structured information package. DeZeeuz N, Bulusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup 8, 1400.

Patients attitudes towards an individualised filofax information system. Kaminski E, DeZeeuz N, Balusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup 8, 1401.

Where do patients seek additional information after a diagnosis of cancer - A multicenre survey. Shingler G, Bulusu R, Thomas R. EJC. (ECCO) 1997. Vol. 33, Sup8, 1426.

Comparison of intralesional and systemically administered radiolabelled MAb in experimental tumours. R Thomas, P Carnochan, S Eccles, M Brada. E J Nuclear Med. Sup.4. Jan 1998.

Video directed information - Patient satisfaction following a diagnosis of cancer. Deary A, Malone L, Jessop L, Akass C, Thomas R. Annuls of Oncology (ESM0) Volume 9, Supplement 4, pp 143.

Anxiety and Depression - Effect on patients preferences for information following a diagnosis of cancer. Thomas R, Brown C, Dalton L, Welton S, Stockton D. Ann of Onc (ESM0) Vol 9, Sup 4, pp 141.

Treatment of platinum-induced anaemia eith epoetin alpha: Attitudes of community and hospital based nursing staff. A Deary and R Thomas. The European J. of Cancer. Vol.35. Suppl.4. p.30 (ab. 92).

Why Oncologist should provide a web site for their patients. L Dalton and R Thomas. The European Journal of Cancer. Vol.35. Suppl.4. p.46 (ab. 164).

Preparatory information on video cassette significantly reduces treatment associated anxiety and depression - A randomised multicentre trial. R Thomas, M Daly, F Delorenzo The European Journal of Cancer. Vol.35. Suppl.4. p.275 (ab. 1101).

Thomas R, Daly M, Dalton L, Perryman B, Stockton D. Preparatory information on video significantly improves treatment associated anxiety, depression and satisfaction - a multicentre study. JCO 1999;Supp 8 (ASCO):1570

Optimising the side effects of raltitrexed with appropriate supportive drugs: a prospective community hospital study. Thomas R, Bulusu R. EJC March 2001 vol 37, supp.2 pp119.

Lyphpoma Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK . R Thomas, J.Sweetman, P Hoskins. EJC March 2001 vol 37, supp.2 pp119

Adjuvant breast cancer Chemotherapy – an audit of neutrpenia, dose intensity, and gcsf use in the UK . R Thomas and R Leonard. EJC March 2001 vol 37, supp.2 pp61

Developing and evaluating a regional patient information strategy. R Thomas, C.Lockery. EJC March 2001 vol 37, supp.2 pp 62

Measuring resposes to received information – development of a patient satisfaction questionnaire. Kaminski E, Thomas R EJC (1396) vol 37 supplement 6 October 2001

Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy. ESMO 2002

Hormone therapy for breast cancer – qol, toxicity and patient preference of letrozole versus anstrozole EJC Proc EBCC 2002, Vol 38, supp 3, anstract 171

Early intervention with Epoetin alfa for treatment of anaemia and improvement of quality of life in cancer patients undergoing myelotoxic chemotherapy.’ H Thomas, R Thomas, K McAdam, J Joffe, E Sugden, S Awwad, LT Tan, P Murray, N Bailey, A Branson. S ESMO , Nice 2002.

What are the costs of not using rhEPO to treat anaemia in cancer?Robert Thomas Focus on Anaemia in cancer. Vol 3, Issue 2, 2002, Supported by Roche.

Empowering patients to make informed treatment decisions based on tolerability, quality of life and patients preference. A compariston of letrozole and anastrazole in a multi-centre, randomised, single blind cross over study. R. Thomas, A. Makris, D. Bloomfield , S. 3^rd European Breast Cancer Conference, Barcelona . 2002. EJC. 38, sup 3, pg S83, No. 171

Empowering patients to make informed treatment decisions based on tolerability, quality of life and patients preference. David J Bloomfield, Robert Thomas, Andreas Makris, Sara Godward and Margaret Moody. 27^th ESMO Congress, Nice, France. Annals of Oncololgy, vol. 13, 2002, supplement 5, pg 32. No. 114PD

Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease. Robert James Thomas, Sara Godward, Madeleine M. Williams, Wassif F. Wassif.Abstract Book of the 27^th ESMO Congress, Supplement 5, Pg 30.

Preliminary phase II results of the salicylate rich formula CV247 in patients with malignant disease. Thomas R, Godward S, Williams M, Wassif W.BOA Annual Scientific Meeting in association with BASO, Cambridge . September 2002.

Examining tolerability, quality of life and patient preference of letrozole versus anastrozole in a multicentre, randomised, single blind cross over study. Makris A, Thomas R, Bloomfield D, Godward S, Moody M. 25^th Annual San Antonio Breast Cancer Symposium. Breast Cancer Research and Treatment. Vol. 76, 2002, 265.

Patient Information – patients in clinical trials are more satisfied. R. Thomas, M, Williams. 2005 EJC , Vol. 3, no.2, pp 384 (ab 1341)

Can we move to a paperless information system? A Deary & R Thomas. 2005 EJC , Vol. 3, no.2, pp 460 (ab 1587).

Can switching to letrozole in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker (26^th San Antonio Breast cancer Conference) Dec 2005. Breast Cancer Research and Treatment ab 2067.

Can switching to letrozole in tamoxifen intolerant post menopausal women improve hot flushes, qol and mood? R Thomas, C Marshall, M Williams, L Walker (31^st ESMO Conference) Oct 2006. Annals of Oncology volume 17, supplement 10

Palonestron – cost effectiveness in clinical community practice. R Thomas, , M Williams, (31^st ESMO Conference) Oct 2006. Annals of Oncology volume 17, supplement 10